Publications by eHealth-Hub Cancer Researchers in 2023

[1] O. Adair, E. McFerran, T. Owen, et al. "A comparison of
international modelling methods to evaluate health economics of
colorectal cancer screening: a systematic review protocol". Eng. In:
_Systematic reviews_ 12.1 (Jan. 2023), p. 14. ISSN: 2046-4053. DOI:
10.1186/s13643-023-02173-w. PMID: 36707908.

[2] A. Aggarwal, A. Choudhury, N. Fearnhead, et al. "The future of
cancer care in the UK-time for a radical and sustainable National
Cancer Plan". Eng. In: _The Lancet. Oncology_ 25.1 (Jan. 2024), pp.
e6-e17. ISSN: 1474-5488. DOI: 10.1016/S1470-2045(23)00511-9. PMID:

[3] R. Amirkhah, K. Gilroy, S. B. Malla, et al. "MmCMS: mouse models'
consensus molecular subtypes of colorectal cancer". Eng. In: _British
journal of cancer_ 128.7 (Mar. 2023), pp. 1333-1343. ISSN: 1532-1827.
DOI: 10.1038/s41416-023-02157-6. PMID: 36717674.

[4] M. Baumann, J. Celis, U. Ringborg, et al. "Engaging European
society at the forefront of cancer research and care: How discussions
at the 5th Gago Conference on European Science policy led to the
Heidelberg Manifesto". Eng. In: _Molecular oncology_ 17.6 (Jun. 2023),
pp. 925-945. ISSN: 1878-0261. DOI: 10.1002/1878-0261.13423. PMID:

[5] I. Bondarenko, A. Agarwal, M. Van Hemelrijck, et al. "Far-reaching
impact of the Russian invasion of Ukraine on global cancer research".
Eng. In: _European journal of cancer (Oxford, England : 1990)_ 183
(Apr. 2023), pp. 95-97. ISSN: 1879-0852. DOI:
10.1016/j.ejca.2023.01.020. PMID: 36812845.

[6] R. Casolino, A. L. Johns, M. Courtot, et al. "Accelerating cancer
omics and precision oncology in health care and research: a Lancet
Oncology Commission". Eng. In: _The Lancet. Oncology_ 24.2 (Feb. 2023),
pp. 123-125. ISSN: 1474-5488. DOI: 10.1016/S1470-2045(23)00007-4. PMID:

[7] N. Couespel, E. Venegoni, and M. Lawler. "The European Cancer
Pulse: tracking inequalities in cancer control for citizen benefit".
Eng. In: _The Lancet. Oncology_ 24.5 (May. 2023), pp. 441-442. ISSN:
1474-5488. DOI: 10.1016/S1470-2045(23)00140-7. PMID: 37142370.

[8] K. B. Eckenrode, D. Righelli, M. Ramos, et al. "Curated single cell
multimodal landmark datasets for R/Bioconductor". Eng. In: _PLoS
computational biology_ 19.8 (Aug. 2023), p. e1011324. ISSN: 1553-7358.
DOI: 10.1371/journal.pcbi.1011324. PMID: 37624866.

[9] D. J. Flanagan, R. Amirkhah, D. F. Vincent, et al. "Author
Correction: Epithelial TGFβ engages growth-factor signalling to
circumvent apoptosis and drive intestinal tumourigenesis with
aggressive features". Eng. In: _Nature communications_ 14.1 (Jan.
2023), p. 522. ISSN: 2041-1723. DOI: 10.1038/s41467-023-36266-w. PMID:

[10] G. J. Greene, C. S. Thomson, D. Donnelly, et al. "Whole-population
trends in pathology-confirmed cancer incidence in Northern Ireland,
Scotland and Wales during the SARS-CoV-2 pandemic: A retrospective
observational study". Eng. In: _Cancer epidemiology_ 84 (Jun. 2023), p.
102367. ISSN: 1877-783X. DOI: 10.1016/j.canep.2023.102367. PMID:

[11] J. Han, M. Rolles, F. Torabi, et al. "The impact of the COVID-19
pandemic on community prescription of opioid and antineuropathic
analgesics for cancer patients in Wales, UK". Eng. In: _Supportive care
in cancer : official journal of the Multinational Association of
Supportive Care in Cancer_ 31.9 (Aug. 2023), p. 531. ISSN: 1433-7339.
DOI: 10.1007/s00520-023-07944-8. PMID: 37606853.

[12] R. H. Henderson, D. French, E. Stewart, et al. "Delivering the
precision oncology paradigm: reduced R&D costs and greater return on
investment through a companion diagnostic informed precision oncology
medicines approach". Eng. In: _Journal of pharmaceutical policy and
practice_ 16.1 (Jul. 2023), p. 84. ISSN: 2052-3211. DOI:
10.1186/s40545-023-00590-9. PMID: 37408046.

[13] M. Lawler, G. Lewison, K. Oliver, et al. "Gender inequity in
cancer research leadership in Europe: Time to act". Eng. In: _European
journal of cancer (Oxford, England : 1990)_ 194 (Nov. 2023), p. 113345.
ISSN: 1879-0852. DOI: 10.1016/j.ejca.2023.113345. PMID: 37813780.

[14] M. Lawler, R. Sullivan, G. K. Abou-Alfa, et al. "Health diplomacy
in action: The cancer legacy of the Good Friday Agreement". Eng. In:
_Journal of cancer policy_ 38 (Dec. 2023), p. 100448. ISSN: 2213-5383.
DOI: 10.1016/j.jcpo.2023.100448. PMID: 37839622.

[15] M. P. Lythgoe, G. Lewison, A. Aggarwal, et al. "The rise of
immuno-oncology in China: a challenge to western dominance?" Eng. In:
_The Lancet. Oncology_ 24.5 (May. 2023), pp. 439-441. ISSN: 1474-5488.
DOI: 10.1016/S1470-2045(23)00026-8. PMID: 37142369.

[16] E. McFerran, V. Cairnduff, R. Elder, et al. "Cost consequences of
unscheduled emergency admissions in cancer patients in the last year of
life". Eng. In: _Supportive care in cancer : official journal of the
Multinational Association of Supportive Care in Cancer_ 31.3 (Mar.
2023), p. 201. ISSN: 1433-7339. DOI: 10.1007/s00520-023-07633-6. PMID:

[17] S. O'Reilly, H. K. Carroll, D. Murray, et al. "Impact of the
COVID-19 pandemic on cancer care in Ireland - Perspectives from a
COVID-19 and Cancer Working Group". Eng. In: _Journal of cancer policy_
36 (Jun. 2023), p. 100414. ISSN: 2213-5383. DOI:
10.1016/j.jcpo.2023.100414. PMID: 36841473.

[18] T. Sessler, G. P. Quinn, M. Wappett, et al. "surviveR: a flexible
shiny application for patient survival analysis". Eng. In: _Scientific
reports_ 13.1 (Dec. 2023), p. 22093. ISSN: 2045-2322. DOI:
10.1038/s41598-023-48894-9. PMID: 38086891.

[19] R. d. M. Simoes, R. Shirasaki, S. L. Downey-Kopyscinski, et al.
"Genome-scale functional genomics identify genes preferentially
essential for multiple myeloma cells compared to other neoplasias".
Eng. In: _Nature cancer_ 4.5 (May. 2023), pp. 754-773. ISSN: 2662-1347.
DOI: 10.1038/s43018-023-00550-x. PMID: 37237081.

[20] K. Taylor, J. Zou, M. Magalhaes, et al. "Circulating tumour DNA
kinetics in recurrent/metastatic head and neck squamous cell cancer
patients". Eng. In: _European journal of cancer (Oxford, England :
1990)_ 188 (Jul. 2023), pp. 29-38. ISSN: 1879-0852. DOI:
10.1016/j.ejca.2023.04.014. PMID: 37182343.

Publications by eHealth-Hub Cancer Researchers in 2022

[1] A. Banerjee, C. Sudlow, and M. Lawler. "Indirect effects of the
pandemic: highlighting the need for data-driven policy and
preparedness". Eng. In: _Journal of the Royal Society of Medicine_
115.7 (Jul. 2022), pp. 249-251. ISSN: 1758-1095. DOI:
10.1177/01410768221095245. PMID: 35537476.

[2] M. Begum, G. Lewison, X. Wang, et al. "Global colorectal cancer
research, 2007-2021: Outputs and funding". Eng. In: _International
journal of cancer_ 152.3 (Feb. 2023), pp. 470-479. ISSN: 1097-0215.
DOI: 10.1002/ijc.34279. PMID: 36082449.

[3] G. Buyens, M. van Balken, K. Oliver, et al. "Cancer literacy -
Informing patients and implementing shared decision making". Eng. In:
_Journal of cancer policy_ 35 (Dec. 2022), p. 100375. ISSN: 2213-5383.
DOI: 10.1016/j.jcpo.2022.100375. PMID: 36462750.

[4] S. M. Corry, A. M. McCorry, T. R. Lannagan, et al. "Activation of
innate-adaptive immune machinery by poly(I:C) exposes a therapeutic
vulnerability to prevent relapse in stroma-rich colon cancer". Eng. In:
_Gut_ 71.12 (Dec. 2022), pp. 2502-2517. ISSN: 1468-3288. DOI:
10.1136/gutjnl-2021-326183. PMID: 35477539.

[5] S. Creedican, C. M. Robinson, K. Mnich, et al. "Inhibition of IRE1α
RNase activity sensitizes patient-derived acute myeloid leukaemia cells
to proteasome inhibitors". Eng. In: _Journal of cellular and molecular
medicine_ 26.16 (Aug. 2022), pp. 4629-4633. ISSN: 1582-4934. DOI:
10.1111/jcmm.17479. PMID: 35822520.

[6] S. Elizabeth, K. Aidan, O. B. David, et al. "Low CD49d expression
in newly diagnosed chronic lymphocytic leukaemia may be associated with
high-risk features and reduced treatment-free-intervals". Eng. In:
_European journal of haematology_ 109.5 (Nov. 2022), pp. 441-446. ISSN:
1600-0609. DOI: 10.1111/ejh.13824. PMID: 35776688.

[7] N. C. Fisher, R. M. Byrne, H. Leslie, et al. "Biological
Misinterpretation of Transcriptional Signatures in Tumor Samples Can
Unknowingly Undermine Mechanistic Understanding and Faithful Alignment
with Preclinical Data". Eng. In: _Clinical cancer research : an
official journal of the American Association for Cancer Research_ 28.18
(Sep. 2022), pp. 4056-4069. ISSN: 1557-3265. DOI:
10.1158/1078-0432.CCR-22-1102. PMID: 35792866.

[8] D. J. Flanagan, R. Amirkhah, D. F. Vincent, et al. "Epithelial TGFβ
engages growth-factor signalling to circumvent apoptosis and drive
intestinal tumourigenesis with aggressive features". Eng. In: _Nature
communications_ 13.1 (Dec. 2022), p. 7551. ISSN: 2041-1723. DOI:
10.1038/s41467-022-35134-3. PMID: 36477656.

[9] G. Greene, R. Griffiths, J. Han, et al. "Impact of the SARS-CoV-2
pandemic on female breast, colorectal and non-small cell lung cancer
incidence, stage and healthcare pathway to diagnosis during 2020 in
Wales, UK, using a national cancer clinical record system". Eng. In:
_British journal of cancer_ 127.3 (Aug. 2022), pp. 558-568. ISSN:
1532-1827. DOI: 10.1038/s41416-022-01830-6. PMID: 35501391.

[10] R. H. Henderson, D. French, E. McFerran, et al. "Spend less to
achieve more: Economic analysis of intermittent versus continuous
cetuximab in KRAS wild-type patients with metastatic colorectal
cancer". Eng. In: _Journal of cancer policy_ 33 (Sep. 2022), p. 100342.
ISSN: 2213-5383. DOI: 10.1016/j.jcpo.2022.100342. PMID: 35718327.

[11] G. Lambe, S. Doran, R. Clifford, et al. "Isolated CNS relapse of
medullary aggressive high-grade B-cell lymphoma on 18F-FDG-PET/CT".
Eng. In: _European journal of hybrid imaging_ 6.1 (May. 2022), p. 9.
ISSN: 2510-3636. DOI: 10.1186/s41824-022-00130-9. PMID: 35501493.

[12] M. Lawler and M. Crul. "Data must underpin our response to the
covid-19 pandemic's disastrous impact on cancer". Eng. In: _BMJ
(Clinical research ed.)_ 376 (Feb. 2022), p. o282. ISSN: 1756-1833.
DOI: 10.1136/bmj.o282. PMID: 35115384.

[13] M. Lawler, L. Davies, S. Oberst, et al. "European
Groundshot-addressing Europe's cancer research challenges: a Lancet
Oncology Commission". Eng. In: _The Lancet. Oncology_ 24.1 (Jan. 2023),
pp. e11-e56. ISSN: 1474-5488. DOI: 10.1016/S1470-2045(22)00540-X. PMID:

[14] M. Lawler and F. Meunier. "Don't make cancer survivors pay
twice-the right for them to be "forgotten" should be law everywhere".
Eng. In: _BMJ (Clinical research ed.)_ 378 (Sep. 2022), p. o2197. ISSN:
1756-1833. DOI: 10.1136/bmj.o2197. PMID: 36130783.

[15] E. Nolte, M. Morris, S. Landon, et al. "Exploring the link between
cancer policies and cancer survival: a comparison of International
Cancer Benchmarking Partnership countries". Eng. In: _The Lancet.
Oncology_ 23.11 (Nov. 2022), pp. e502-e514. ISSN: 1474-5488. DOI:
10.1016/S1470-2045(22)00450-8. PMID: 36328024.

[16] G. P. Quinn, T. Sessler, B. Ahmaderaghi, et al. "classifieR a
flexible interactive cloud-application for functional annotation of
cancer transcriptomes". Eng. In: _BMC bioinformatics_ 23.1 (Mar. 2022),
p. 114. ISSN: 1471-2105. DOI: 10.1186/s12859-022-04641-x. PMID:

[17] P. Robbe, K. E. Ridout, D. V. Vavoulis, et al. "Whole-genome
sequencing of chronic lymphocytic leukemia identifies subgroups with
distinct biological and clinical features". Eng. In: _Nature genetics_
54.11 (Nov. 2022), pp. 1675-1689. ISSN: 1546-1718. DOI:
10.1038/s41588-022-01211-y. PMID: 36333502.

[18] R. Sullivan, G. Lewison, J. Torode, et al. "Cancer research
collaboration between the UK and the USA: reflections on the 2021 G20
Summit announcement". Eng. In: _The Lancet. Oncology_ 23.4 (Apr. 2022),
pp. 460-462. ISSN: 1474-5488. DOI: 10.1016/S1470-2045(22)00079-1. PMID:

[19] H. Van Poppel, N. M. L. Battisti, M. Lawler, et al. "European
Cancer Organisation's Inequalities Network: Putting Cancer Inequalities
on the European Policy Map". Eng. In: _JCO global oncology_ 8 (Oct.
2022), p. e2200233. ISSN: 2687-8941. DOI: 10.1200/GO.22.00233. PMID:

[20] Y. Wang, A. Buck, M. Grimaud, et al. "Anti-CAIX BBζ CAR4/8 T cells
exhibit superior efficacy in a ccRCC mouse model". Eng. In: _Molecular
therapy oncolytics_ 24 (Mar. 2022), pp. 385-399. ISSN: 2372-7705. DOI:
10.1016/j.omto.2021.12.019. PMID: 35118195.
No matching items